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ABSTRACT: Increasing antibiotic resistance among uropa-
thogenic Escherichia coli (UPEC) is driving interest in
therapeutic targeting of nonconserved virulence factor (VF)
genes. The ability to formulate eﬃcacious combinations of
antivirulence agents requires an improved understanding of
how UPEC deploy these genes. To identify clinically relevant
VF combinations, we applied contemporary network analysis
and biclustering algorithms to VF proﬁles from a large,
previously characterized inpatient clinical cohort. These
mathematical approaches identiﬁed four stereotypical VF combinations with distinctive relationships to antibiotic resistance
and patient sex that are independent of traditional phylogenetic grouping. Targeting resistance- or sex-associated VFs based upon
these contemporary mathematical approaches may facilitate individualized anti-infective therapies and identify synergistic VF
combinations in bacterial pathogens.
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Antibiotic resistance is widely recognized as one of the 21stcentury’s pre-eminent public health challenges. There is
also a growing appreciation that conventional broad-spectrum
antibiotic strategies exert deleterious “oﬀ-target eﬀects” on the
human microbiome.1,2 Antibiotic therapies for urinary tract
infections (UTIs), which are predominantly caused by
uropathogenic Escherichia coli (UPEC), have come to exemplify
both challenges. UPEC are becoming notably resistant to the
potent oral trimethoprim/sulfamethoxazole and ﬂuoroquino-
lones that have long been a mainstay of outpatient UTI
therapy,3,4 presenting an increasing healthcare burden.5
Fluoroquinolone use has also been implicated in the rise of
community-acquired Clostridium diﬃcile, an opportunistic
infection that takes root when the intestinal microbiome is
disturbed by antibiotic exposure.6 These shortcomings of
current broad-spectrum antibiotic approaches have motivated
renewed interest in precision therapeutic approaches directed
against pathogen-speciﬁc molecular targets that circumvent
existing resistance mechanisms and spare beneﬁcial members of
the gut microbiome. Chief among these are antivirulence agents
that selectively disarm pathogenic functions in bacteria without
suppressing beneﬁcial functions of intestinal microbes.7
Prior studies, aided by UPEC’s genetic tractability, have
identiﬁed numerous monogenic urovirulence determinants in
clinical E. coli isolates. Many of these genetic loci, termed
virulence factors (VFs), are nonconserved or are carried on
mobile genetic elements and are known to execute speciﬁc
biochemical functions related to uropathogenesis.8 The
biochemical functions of many VFs are known in suﬃcient
detail to permit prototype antivirulence therapeutic agents to
be identiﬁed or developed. VFs associated with iron acquisition
systems (siderophores9), in particular, have been targeted by
biosynthetic inhibitors,10 import inhibitors, and “Trojan horse”
toxins such as pesticin, albomycin, and microcins.11−14 E. coli
adhesins have also been targeted for inhibition in approaches
that could be expanded to other adhesin types.15−17 Continued
eﬀorts are likely to provide an expanded panel of antivirulence
agents that may be combined to maximize clinical eﬃcacy.
An important theoretical weakness of antivirulence therapies
arises from the targets’ potentially brief period of pathophysio-
logically relevant activity, which may limit an agent’s eﬃcacy.
Just as uropathogenic adaptations are generally multifactorial in
nature, antivirulence agents will likely have to be combined for
eﬃcacy.18,19 In addition to increasing eﬃcacy, combination
drug approaches typically limit the rate at which resistant
mutants emerge by forcing pathogens to develop multiple
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simultaneous resistance adaptations. These principles underlie
current combination anti-infective therapies against Helicobacter
pylori, Mycobacterium tuberculosis, and HIV. Although combined
siderophore and adhesin inhibitor therapy may be similarly
eﬀective against uropathogenic E. coli, it has been unclear how
to optimally combine these agents to best treat urological
infections. Currently unexplored associations between UPEC
VFs further complicate combination antivirulence therapeutic
formulations for UTI.
To determine which antivirulence target combinations
predominate in patients, we applied mathematical network
community detection and statistical biclustering to uropatho-
genic E. coli VF genotypes from a previously described
hospitalized UTI patient cohort with a high incidence of
antibiotic resistance, pyelonephritis, and bacteremia.20 The
mathematical tools used here21−23 simultaneously considered
VF genotypes and their frequency among 337 clinical
pathogenic isolates and identiﬁed 4 stereotypical urovirulence
strategists. These strategists were independently associated with
antibiotic resistance and patient sex. These results provide a
preliminary framework for devising and prioritizing combina-
torial antivirulence strategies and support the use of these
mathematical approaches to address this and other unresolved
questions in infectious diseases.
■ RESULTS AND DISCUSSION
Clinical Isolate Characteristics. Three hundred and
thirty-seven bacteriuric inpatient E. coli clinical isolates (CIs)
were derived from a recently described inpatient cohort
collected over the course of one year (Table 1).20 The CIs
characterized in this study were predominantly female (n = 263,
78%), with a median inpatient age range of 62 years (range,
19−101 years). One hundred and seven patients had
pyelonephritis (32%), 60 had sepsis-induced hypotension
(17%), and 24 had bacteremia (7%). The E. coli phylogenetic
group distribution was typical of urinary isolates, with a
majority of strains contained in group B2 (68%).24 One
hundred and seventeen isolates were resistant to ciproﬂoxacin
(CIP, 35%), and 96 were resistant to trimethoprim/
sulfamethoxazole (TMP/S, 29%).
Virulence Factor Distribution. CIs were assessed for the
presence or absence of 16 VF genes (Table 2) that have been
collectively addressed in over 2700 publications (Figure S1).
One hundred and twenty-seven unique, nonredundant VF
genotypes were present among the clinical isolates examined in
this study. Virulence factor prevalence ranged from highly
common (chuA; 84%) to infrequent (Dr; 7%, Figure 1a). Using
a z test for normality, we found that the gene content is not
normally distributed (p = 0.031). Indeed, a histogram of VF
Table 1. Clinical Characteristics of Clinical Isolates Tested
in This Study
metric total (%)
female 263 (78)
male 74 (22)
pyelonephritis 107 (32)
sepsis-induced hypotension (SIH) 60 (17)
bloodstream infection (BSI) 24 (7)
ciproﬂoxacin (CIP) resistant 117 (35)
trimethoprim/sulfamethoxazole (TMP/S) resistant 96 (29)
phylogenetic group B2 232 (68)
phylogenetic group D 54 (16)
phylogenetic group B1 41 (12)
phylogenetic group A 10 (3)
Table 2. Virulence Factors and Their Functions
gene function
chuA E. coli heme uptake
f yuA siderophore (yersiniabactin uptake)
ompT surface protease
tspE anonymous DNA fragment
yjaA hypothetical protein
usp bacteriocin
capII group II capsule antigen
iucD siderophore (aerobactin)
iha irgA homologue adhesin
sat secreted autotransporter toxin
prf adhesion (P-related ﬁmbriae)
iroN siderophore (salmochelin)
hlyA hemolysin
sfa adhesion (S-ﬁmbriae)
cnf1 cytotoxic necrotizing factor
Dr adhesion (Dr family)
Figure 1. Virulence factor incidence and distribution among the
clinical isolates examined in this study: (a) Virulence factor incidence
in the 337 clinical isolatesi shown. (b) Each virulence factor (VF) was
assigned a score of 1. Any virulence score ≥1 indicates the presence of
one or more VFs, and 0 is the absence of individual genes. Because the
presence and absence of all 16 genes were considered, the VF score
ranged from 0 to 16. Next, a data matrix was generated to determine
each clinical isolate’s VF proﬁle. A bimodal distribution of virulence
scores was observed among 337 clinical isolates, with local maxima at
one and nine virulence factors.
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gene content frequency reveals a bimodal distribution with local
maxima at one and nine virulence factors (Figure 1b). This
bimodal distribution is consistent either with two quantitative
optima for VF content or with the tendency of VFs to occur in
modular combinations. An overview by principal component
analysis (PCA) did not clearly resolve any coherent patterns in
this data set (Figure S2).
Network Community Detection of Uropathogenic
Strategies. To determine whether UPEC VFs are associated
with each other in stereotypical patterns, we next applied
modularity-based community detection to a network of the 16
VFs alone. We set weighted edges between VFs by statistically
signiﬁcant positive correlations (by Fisher’s exact test at the
1.5% one-sided level to ensure a single component connecting
all 16 VFs). Three interrelated VF communities are discernible
within the resulting heatmap (Figure 2a), corresponding force-
directed layout (Figure 2b), and VF nested hierarchy of
communities (Figure 2c). Siderophore genes are uniquely
represented in each VF community (VF community 1, f yuA;
VF community 2, iroN; VF community 3, iucD). Weaker
positive correlations between the f yuA-containing VF com-
munity and those containing iucD or iroN are evident in the VF
adjacency matrix. Network community detection thus shows
that the clinical E. coli isolates deploy VFs in stereotypical
combinations.
Network Community Detection of Clinical Isolates. To
determine whether UPEC carry stereotypical VF combinations,
we applied modularity-based community detection to a
network representation of the 337 clinical isolates. We deﬁned
a CI network of positively associated pairs after correcting for
each VF’s mean frequency and variance across the study
population (see Methods for details). Modularity-based
community detection resolves four clinical isolate communities
(CI communities 1−4, n = 45, 118, 76, and 98, respectively),
representing four distinct virulence strategists (Figure 3a). Each
community contains distinctive VF patterns that together
encompass multiple functional classes. A force-directed layout
of this network indicates connectivity and strength of
association between UPEC isolates (Figure 3b). These
stereotypical distributions suggest that virulence genes are
present as modular communities from which relevant
antivirulence targets can be prioritized.
Biclustering Analysis. As a complementary alternative to
network community detection, we employed an iterative binary
biclustering method based on the large average submatrix
(LAS) procedure described by Shabalin et al.23 Whereas
network-based community detection assigns each VF or clinical
isolate to a single community, biclustering simultaneously
identiﬁes highly co-occurring VFs and CIs. A CI or VF may
belong to multiple biclusters (BCs) or none at all. Four BCs
emerge from our clinical population (BC 1−4, n = 234, 112, 62,
and 39, respectively; Figure 4a), in a manner consistent with
the four virulence strategists identiﬁed by network community
detection. Overall, VFs associated with each bicluster are highly
expressed across the constituent CIs (>72%). Biclustering did
not classify 62 CIs with low VF gene content, the collection of
which grossly resembles CI community 4. BC 4 is mostly
redundant with BC 1 but is most distinguished by the absence
of two genes (sfa and cnf1) and the low prevalence of four
genes (yjaA, usp, iroN, and hlyA). The most abundant
classiﬁcations resemble the CI communities, with the largest
single bicluster combination (BC1+2, strains appearing in BC1
and BC2 but no other BCs, n = 89) closely resembling CI
community 2. By annotating the force-directed layout of the CI
strains with bicluster assignments, we reveal many similarities
between the two clustering results (Figures 3b and 4b). The
stereotypical VF combinations identiﬁed by both mathematical
approaches deﬁne four stereotypical virulence strategists among
UPEC in the study population.
Figure 2. Network community detection clusters 16 virulence factors
into three discrete communities. (a) Three VF communities are
evident in an empirical heatmap depicting statistically signiﬁcant
positive correlations between VFs. (b) A force-directed layout
illustrates connectivities between individual virulence factors (VFs)
organized into three VF communities (colors). (c) Nested hierarchy of
communities of VF genes in a polar coordinate dendrogram are
colored according to community identiﬁcation at default resolution
(three communities). Each VF community contains a distinct
siderophore gene (iroN, f yuA, iucD).
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Virulence Strategists and Phylogeny. E. coli phyloge-
netic groups have been used extensively to classify clinical E.
coli isolates and consistently associate group B2 with
extraintestinal infections. We investigated whether CI phyloge-
netic groups are more informative than the stereotypical VF
communities by seeking associations with CI communities and
biclusters (Table S1). Assignment to non-B2 phylotypes is
associated with C4, BC4, or nonbiclustered strains. Phyloge-
netic type otherwise exhibited no other clear associations with
other VF-deﬁned groupings. These results reveal that the best-
resolved virulence strategies represent an organizational level
that is distinct from phylogenetic grouping.
Virulence Strategists and Siderophores. Network
community detection and biclustering each identify collections
that possess stereotypical combinations of siderophores, toxins,
and adhesins. Among single functional classes, siderophore
genotypes eﬀectively distinguish these communities and
biclusters from one another. E. coli siderophores exhibit diverse
structures that likely represent evolutionary adaptive radiation
such that one siderophore system may represent a gain of
function, whereas another may represent functional redun-
dancy.25−28 Siderophore systems have also been subject to
extensive targeted drug development studies in bacteria.13,29
We therefore examined siderophore genotypes as an
independent way to characterize UPEC strategists. Overlaying
siderophore genotypes on the force-directed layout (Figure 4c)
reveals this nonrandom siderophore gene distribution. We
observed that a representative siderophore genotype character-
Figure 3. Network community detection clusters 337 inpatient clinical
isolates into four discrete communities. (a) Four distinct communities
(identiﬁed using modularity maximization) describe the CIs in this
population. Color scale: dark blue, VF presence = 100%; white, ≤5%.
(b) A force-directed layout illustrates associations between virulence
factor (VF) proﬁles of individual UPEC clinical isolates (CIs). Each
node represents a CI, and connecting line (edge) lengths are
determined to most closely match the connectivity level between
the connected CIs (colored by CI community assignment).
Figure 4. Bicluster and siderophore gene composition cluster clinical
isolates similarly to network analysis. (a) Four biclusters describe 82%
of the CIs in this population. Siderophore genes are in bold type.
Color scale: dark blue, VF presence = 100%; white, ≤5%. (b, c) The
force-directed layout for clinical isolates overlaid with each CI’s
bicluster assignments (b) and siderophore genotype (c) illustrates
overall similarities between these CI classiﬁcation approaches and the
communities in Figure 1b.
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izes each CI community (CI community 1 is 88.9% f yuA only;
CI community 2 is 93.2% f yuA+iucD; community 3 is 51.3%
f yuA+iroN; CI community 4 is 46.9% none). Similarly,
representative siderophore genes characterize each BC (BCs
1 and 4 are 61.9% and 34.5% f yuA only, respectively; BC 1+2 is
94.4% f yuA+iucD; BC 3 is 100% iroN). Siderophore genotypes
are thus strongly associated with the virulence strategists
identiﬁed by network community detection and bicluster
analysis.
Figure 5. CI classiﬁcations correspond to antibiotic resistance and patient sex. Patient sex and antibiotic resistance (bars) in each clinical isolate
subgroup relative to total study population (dashed lines) are shown. Subgroup size (#) is indicated in the bottom row. Small subgroups (<6 CI)
were omitted for clarity. f yuA+iucD strategists (community 2, BC1+2) exhibit notable sex and ciproﬂoxacin resistance associations. Statistical
signiﬁcance determined by Fisher’s exact test is indicated by number of asterisks (p values: 0.05, 0.01, and 0.001, respectively, without correction for
multiple testing).
Table 3. Patient Sex and E. coli Virulence Groupings Are Strongly Associated with Ciproﬂoxacin (CIP) and Trimethoprim/Sulfa
(TMP/S) Resistancea
nested multivariate analysis logistic regression analysis
antibiotic model deviance covariate OR
CIP sex 415*** male 3.5 (2.0−6.0)***
sex + CI communities 287*** C2 15.0 (6.0−47.0)***
male 3.9 (1.9−8.2)***
C4 4.0 (1.4−11.0)*
sex + biclusters 322*** male 4.7 (2.4−9.6)***
BC 1+2 2.1 (1.0−4.7)*
BC 1 0.4 (0.2−0.9)*
sex + siderophore genotype 294*** f yuA+iucD 8.0 (5.0−15.0)***
male 4.1 (2.1−8.6)***
TMP/S sex 405
sex + CI communities 382*** C3 0.2 (0.1−0.4)***
sex + biclusters 380*** BC 1+3 0.1 (0.0−0.3)***
BC 1+2+3 0.1 (0.0−0.5)*
BC 1 0.5 (0.2−0.9)*
BC 1+2 0.4 (0.2−0.9)*
sex + siderophore genotype 373*** f yuA+iucD 2.0 (1.4−3.7)**
f yuA+iroN 0.1 (0.0−0.5)**
aIn the nested multivariate analyses, lower deviance indicates improved ﬁt to the model. In the logistic regression analyses, odds ratios (OR) of
resistance per covariate are shown (with 95% conﬁdence intervals). Only the statistically signiﬁcant variables from each model are listed for clarity. *,
p < 0.05; **, p < 0.01; ***, p < 0.00001.
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Virulence Strategists and Patient Sex. To assess the four
virulence strategists’ clinical signiﬁcance, we ﬁrst investigated
associations with patient sex, an organizing principle in UTI
medical management. The abundant f yuA+iucD strategists (CI
community 2, BCs 1+2) are highly associated with male sex
(33.1, 32.6, and 30.2%, respectively, compared to the 22% male
study population; each deviation is statistically signiﬁcant as
indicated in Figure 5). Female sex, classically a UTI-susceptible
population, is predominantly associated with f yuA strategists
(CI community 1 and BC 4; 8.9 and 10.3% male, respectively).
Sex preferences among diﬀerent virulence strategists may reﬂect
their preferential adaptation to sex-dependent host niches such
as the vaginal mucosa, the prostate and its secretions, urethral
length, sex diﬀerences in immune defenses, hormonal diﬀer-
ences, or a combination thereof. These ﬁndings suggest that
some antivirulence strategies may be particularly useful in a
precision medicine context where individual patient factors
such as sex guide therapeutic selection.
Virulence Strategists and Antibiotic Resistance. To
determine whether the four virulence strategists are linked with
antibiotic resistance, we investigated associations with pheno-
typic resistance to the two frequently used oral antibiotics
trimethoprim-sulfamethoxazole (TMP/S) and ciproﬂoxacin
(CIP) (Figure 5). The abundant f yuA+iucD strategists (CI
community 2 and BC 1+2; 68.6 and 73.2% total siderophore
genotypes, respectively) are highly associated with CIP
resistance and moderately associated with TMP/S resistance
(Figure 5). Conversely, the f yuA+iroN siderophore genotype
(CI community 3, BC 1+3) is highly susceptible to both CIP
and TMP/S. These results indicate that virulence strategies are
linked to antibiotic responses. Combinatorial targeting of the
f yuA+iucD siderophore genotype may thus represent an
alternative antivirulence strategy against UPEC strains that
are resistant to standard antibiotic therapies.
Multivariate Analysis. Because virulence strategists were
associated with both patient sex and antibiotic resistance
(Figure 5), we used nested multivariate logistic regression
analyses to determine whether virulence strategies and patient
sex contribute independently to antibiotic resistance (Table 3).
Incremental addition of VF content to patient sex in the nested
model reveals that VF groupings (CI communities, biclusters,
or siderophore genotype) are associated independently with
antibiotic resistance. To determine which virulence strategists
are associated with resistance, we conducted logistic regression
analyses with models including each of the three nested
strategies. In these analyses, male sex and f yuA+iucD side-
rophore genotype (CI community 2, BC 1+2) are independ-
ently associated with CIP resistance, whereas TMP/S resistance
is associated with the f yuA+iucD siderophore genotype (but not
CI community 2 or BC 1+2). Conversely, the f yuA+iroN
siderophore genotype (CI community 3, BC 1+3) and BC 1,
BC 1+2, and BC 1+2+3 are each strongly associated with
TMP/S susceptibility, whereas patient sex is not. Virulence
strategies are associated with antibiotic resistance independ-
ently of the sex of the patients from whom they were recovered.
Targeting speciﬁc virulence strategists in this population
therefore suggests new treatment strategies for antibiotic-
resistant uropathogens.
The contemporary mathematical exploratory tools used here
show that E. coli VFs tend to exist in stereotypical
combinations, which deﬁne unique bacterial “strategists”, in
bacteriuric specimens from a well-characterized patient cohort.
Intriguingly, discrete uropathogenic strategists are associated
with the clinically important variables of antibiotic resistance
and patient sex. These clinical associations suggest that speciﬁc
VF combinations are worthy of further consideration as
combinatorial antivirulence therapeutic targets. Furthermore,
the tendency for antibiotic-resistant E. coli to carry VF
communities associated with yersiniabactin ( f yuA) and
aerobactin (iucD) genes suggests new therapeutic targets for
uropathogenic isolates in which existing antibiotics are failing.
The striking increase in ciproﬂoxacin-resistant (CIPR)
isolates at the study institution over the past 15 years (Figure
6a) parallels the worldwide trend30 and prompts a closer look
at the virulence strategy−CIPR association. Mining the
extensive literature on worldwide ﬂuoroquinolone resistance
in UPEC suggests that the virulence strategists identiﬁed in this
study may correspond to other geographic locations. In the
present study, 75% of CIPR isolates possess f yuA+iucD, whereas
none have the f yuA+iroN siderophore genotype (Figure 6b,c).
Similar monogenic E. coli siderophore correlates of CIPR were
observed in studies examining nonclonal strains from China,
Italy, Iran, Israel, Korea, and Australia.31−36 Furthermore, when
genetically distinct CIPR E. coli strains (ST131, ST1193, and
O15:K52:H1) from geographically distinct locations were
characterized by full genome sequencing, aerobactin genes
(iucD, iutA) were present and salmochelin genes (iroBCDEN)
were absent.37−39 Interestingly, CIPS correlates were correlated
with iroN expression in studies conducted in India and
France.40,41 Whereas a more systematic international compar-
ison would be more deﬁnitive, these results suggest that
antivirulence strategies targeting f yuA+iucD strategists would be
preferentially eﬀective against CIPR E. coli in geographically
diverse populations. This connection between virulence and
resistance is unexpected, and the reason for it remains unclear.
Figure 6. Siderophore genotypes as correlates of CIP resistance (CIPR). (a) CIPR rates among E. coli at Barnes-Jewish Hospital from 2000 to 2013
are shown. The gray bar corresponds to the collection period for the clinical isolates examined in this study. (b) Most CIPR urinary E. coli isolates are
f yuA+iucD strategists, whereas (c) all f yuA+iroN strategists are CIPS.
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The existence of stereotypical virulence strategists across
multiple phylogenetic types (the main communities detected
here contain both phylogenetic group B2 and non-B2 strains)
in bacteriuric isolates suggests an underlying pathophysiologic
basis for VF community composition. In the evolutionary
paradigm, VFs with complementary activities are expected to
possess a selective advantage, whereas a noncomplementary VF
may confer a metabolic penalty.42 Pathogenic success in these
bacteria may thus be a more qualitative phenomenon than the
sum total of virulence factors alone (the “virulence score”)
would suggest. The sex-selective strategists observed here raise
the possibility that the iucD-associated VF community confers
greater ﬁtness for a male pathophysiologic niche such as
prostate tissue. It is less clear why the same VF community is
associated with antibiotic resistance, although this could be
associated with distinctive antibiotic uses in male patients or
occupation of a niche that facilitates resistance. Possible
contributions from local circulating E. coli clones, plasmids,
phages, or antibiotic use patterns to the results are also unclear.
Much remains to be learned about the biology and therapeutic
implications of the combinatorial strategists identiﬁed here.
Although the VF genes assessed here are almost certainly an
incomplete list, application of the mathematical approaches
described here to more extensive genetic data from a
geographically more diverse patient cohort would help to
evaluate the interpretations above.
By resolving meaningful associative patterns from heteroge-
neous clinical isolates, contemporary exploratory tools such as
network analysis oﬀer signiﬁcant advances over traditional
monogenic analyses. Additionally, these approaches are
insensitive to additive or synergistic VF combinations that
enhance pathogen virulence or antagonistic combinations that
reduce it. Whereas network community detection ampliﬁes
signal from noise to identify superstructures in the data, the
complementary biclustering approach described here simulta-
neously identiﬁes related E. coli strains and virulence factors
that signiﬁcantly interact. By oﬀering a simpliﬁed relational
superstructure of the data, they also account for the possibility
of clonality in a complex pathogenic data set. It is notable that
network analysis and biclustering identiﬁed VF communities
that mirror the evolutionary relationships proposed above.
Basically, network analysis identiﬁes VF pairs that are most
successful in the study population (i.e., most strongly associated
with each other relative to chance) and progressively assembles
these into an interrelated network based upon these pairwise
interactions. In contrast, more restrictive methods such as PCA
and hierarchical clustering (Figures S2 and S3) do not capture
the interacting gene groups identiﬁed in this study. Analyzed
with diﬀerent tools, the choice of antivirulence targets is thus an
extension of their evolutionary interrelationships. Targeting
these synergistic combinations would lower selective pressure
for antibiotic resistance and minimize the impact on
commensal bacteria, presenting a major advance in infection
pharmacotherapy.
■ METHODS
Study Design, Data Collection, Laboratory Analyses,
and Deﬁnitions. The samples were collected as part of a 1
year (August 1, 2009, to July 31, 2010) Washington University
Institutional Review Board-approved prospective study of
patients with E. coli bacteriuria (>5 × 104 colony-forming
units (CFU)/mL) described by Marschall et al.20 These urine
cultures were obtained as part of the clinical workup for these
patients and were then processed at the hospital’s medical
microbiology laboratory. Clinical isolates were retrieved directly
from this laboratory once bacteriuric patients were identiﬁed in
the hospital’s patient database. Strains without associated blood
culture data were not excluded from this study. Brieﬂy, clinical
isolates were collected from male and female patients with
signiﬁcant bacteriuria. Bacterial DNA was extracted using a
QIAamp DNA mini kit (Qiagen, Valencia, CA, USA). DNA
probes for virulence genes were developed as previously
described20 by the molecular epidemiology laboratory at the
University of Michigan’s School of Public Health, and the
presence of these genes was determined by dot-blot hybrid-
ization using a previously described microarray system43 (Table
1). This method is based on established cDNA glass microarray
fabrication and hybridization techniques that are modiﬁed by
printing total bacterial genomic DNA on the slide. The
hybridization signal is determined by both the target
concentration in the spot and the quantity of the ﬂuorescent
tag carried by the probe, both of which were empirically
optimized by Zhang et al.43 DNA concentration was controlled
for in a separate quantiﬁcation step, utilizing 16S rRNA PCR.
Whereas the clinical isolate collection dates varied, laboratory
processing and analysis were concentrated over a small number
of deﬁned sessions, each of which included appropriate
controls.
The E. coli phylogenetic group was determined from
hybridization results using the triple genotyping method of
Clermont et al.44 Antimicrobial susceptibility was determined
using disk diﬀusion tests (Kirby−Bauer). In this commonly
used test, bacterial growth is observed in response to a standard
concentration of a particular antibiotic. Resistance is deﬁned by
employing Clinical and Laboratory Standards Institute (CLSI;
Wayne, PA, USA) standards for measuring the zone of
inhibition around the antibiotic-impregnated disk and compar-
ing it to a standard interpretation chart.45 Only three isolates
qualiﬁed as moderately resistant by this measure (the rest were
either resistant or susceptible) and were qualiﬁed as resistant
for the purposes of this study. Bacteriuria was deﬁned as ≥5 ×
104 CFU/mL in noncatheterized patients and ≥5 × 103 CFU/
mL in catheterized patients, as well as by using the patients’
documented urinary symptoms. Pyelonephritis was deﬁned as
the presence of ﬂank pain and tenderness and/or fever; sepsis
and sepsis-induced hypotension were deﬁned using established
clinical criteria. The Microbiology Laboratory at Barnes-Jewish
Hospital provided clinical antibiogram data.
Network Analysis. The (bipartite) clinical-isolates-by-
genes binary data array was projected onto two separate
(unipartite) network representations, one each for the clinical
isolates and for the VFs. The VF network, connected by similar
co-occurrences across the clinical isolate population, was
deﬁned by statistically signiﬁcant positive correlation coef-
ﬁcients between VF pairs. Statistical signiﬁcance was
determined by Fisher exact tests on 2 × 2 contingency tables;
for each pair of genes the 2 × 2 contingency table of the
number of expressed and not-expressed outcomes for each of
these two genes was tabulated, and then a Fisher exact test was
used to determine whether or not the two genes appeared
independently within the population of clinical isolates,
conditional on their observed marginal frequencies in the
population. A 1.5% p value threshold (one-tailed on the right,
without correction for multiple testing) was chosen to ensure
that the resulting network of VFs was a single connected
component. An edge was deﬁned as present between any pair
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of positively correlated genes that satisﬁed the threshold, and
then the positive weight of that edge was set by the correlation
coeﬃcient. To continue to respect the diversity of background
VF expression frequencies, we deﬁne the network of clinical
isolates in terms of the column-standardized version of the
clinical-isolates-by-VFs data array; that is, each column is
centered to zero and rescaled to unit variance. The resulting
column-standardized matrix M yielded the full matrix of
correlation coeﬃcients between VFs through the expression
MTM/(n − 1), where n is the number of clinical isolates. For
symmetry, we deﬁned the clinical isolates adjacency matrix, the
(i,j) element of which indicates the presence and weight of the
edge connecting nodes i and j, from the matrix product MMT,
thresholding the elements to retain all positive elements of the
resulting matrix product. We set the diagonals of both
adjacency matrices to zero (no self-loops).
Community detection of the clinical isolate and VF networks
was performed by maximizing modularity with a resolution
parameter, by a generalized implementation of the Louvain
method followed by Kernighan−Lin node-swapping
steps.21,22,46,47 Networks were partitioned into various numbers
of communities by varying the resolution parameter (γ index,
Figure S4). This parameter appears directly in the deﬁnition of
modularity and optimizes community selection. Through this
procedure, a collection of nested VF network partitions was
identiﬁed (as visualized in the main text). For the network of
CIs, closely similar four-community partitions were identiﬁed in
a range of gamma values straddling its default value (γ = 1.0),
so we restricted our attention to a four-community partition
found at that default resolution.
Biclustering. Biclustering is a popular statistical tool for
exploratory analysis of high-dimensional data.48 Given a matrix
of genes by isolates, the goal of biclustering is to group the rows
and columns to ﬁnd “dense” regions of the matrix, that is,
groups of VFs similarly expressed by subsets of isolates. The
expression proﬁle is a binary structure where values for each
clinical isolate indicate expression of a VF (0 = absence, 1 =
presence). A binary version of large average submatrices (LAS)
was used to exhaustively search the 337 × 16 condition matrix
for all statistically signiﬁcant biclusters of large average
expression.23
This method operates in an iterative-residual fashion and is
driven by a Bonferroni-based signiﬁcance score that trades oﬀ
between submatrix size and average value. The method
identiﬁed statistically signiﬁcant large average biclusters, in
the sense that the VFs are expressed across the collection of
clinical isolates more often than expected within the entire
population. The signiﬁcance of an identiﬁed k × l bicluster U is
measured through a binary score function
τ= − − −⎜ ⎟⎜ ⎟
⎡
⎣⎢
⎛
⎝
⎞
⎠
⎛
⎝
⎞
⎠
⎤
⎦⎥S U
m
k
n
F k k p( ) log ( ; , 1 )S S S
where F(τ;kl;1 − p) gives the null probability that the kl entries
of U have τ or more 1s. The probability inside the logarithm is
a Bonferroni-corrected p value associated with observing a
submatrix with an average at least as large as U. The algorithm
was set to ﬁnd biclusters with score S(U) ≥100.
Statistical Analysis. A multivariate logistic regression
model was used to identify covariates signiﬁcantly associated
with antibiotic resistance. The ﬁtted model included indicator
(0/1) covariates for sex, community containment, bicluster
containment, and siderophore content. The covariates with
statistically signiﬁcant coeﬃcients (p value < 0.10) for each
antibiotic (CIP and TMP/S) are shown in Table 3. A nested
models approach was used to determine the signiﬁcance of
variability in antibiotic resistance (CIP and TMP/S) explained
by the inclusion of covariates describing sex, community
containment, bicluster containment, and siderophore type. The
null model contained only the mean response for resistance to
CIP and TMP/S, respectively. Sequentially, each of the above
covariates was added to the null model, and the variability
explained in the model was recorded. To test the signiﬁcance of
the added covariate type, an analysis of deviance was employed
wherein a χ2 test was used to test the reduction in deviance
from the null model. The models and test results are shown in
Table 3. PCA and hierarchical analysis were conducted using
MATLAB.
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